Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
Acute Lymphoid Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Chronic Myeloid Leukemia (CML)|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia
RADIATION: Hyperfractionated total body irradiation|DRUG: Thiotepa|DRUG: Cyclophosphamide|DRUG: Busulfan|DRUG: Fludarabine|DRUG: Melphalan|DRUG: Clofarabine|PROCEDURE: HPC(A) stem cell allograft|DRUG: Rituximab|DEVICE: Rabbit antithymocyte globulin
the Number of Incidences of Grade 3-4 Acute GVHD, The intervention will be considered unpromising if the rate of GVHD is greater than 40% and promising if the rate is 20% or less. Number of participants with and without SAE will be evaluated., 2 years
This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.